V

VERTANICAL

Develops cannabinoid-based therapies for chronic pain

Director Clinical Development

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeGräfelfing, GermanyNo salary listed

About the Job

Requirements

  • A completed MS/MA, M.D., or PhD in natural sciences, medicine, pharmacy, or a comparable field.
  • At least 4–6 years of professional experience, ideally in a top strategy consultancy or a dynamic start-up environment.
  • Fluent German and English.
  • Strong analytical skills, a results-oriented work approach, and attention to detail.
  • Clear and structured communication.

Responsibilities

  • Take operational responsibility for Clinical and Preclinical Science, Medical Writing, Medical Monitoring, and Clinical Safety, reporting directly to executive management.
  • Disciplinarily lead and develop a team of more than five employees.
  • Design clinical study protocols with key opinion leaders, define inclusion and exclusion criteria, and take responsibility for patient safety.
  • Prepare clinical trial applications, study reports, and clinical dossiers for marketing authorization applications, and handle communications concerning regulatory authority inquiries.
  • Develop the clinical study program strategy, including selection of new indications.
  • Lead the selection and management of external service providers, including negotiation of project budgets.
  • Own and optimize processes in the assigned areas and continuously develop the organizational target model.

Desired Qualifications

  • Experience in a top strategy consultancy or a dynamic start-up environment is ideal.

About the Company

VERTANICAL

Develops cannabinoid-based therapies for chronic pain

VERTANICAL develops therapies for chronic pain. Its lead product, VER-01, is a cannabinoid-based treatment designed to relieve pain and also help with common comorbid problems like sleep disorders and reduced physical function. The company aims to move beyond simple pain relief by addressing multiple related symptoms and to set new standards in pain therapy with VER-01 becoming the leading treatment for chronic pain by 2030. Compared with competitors, VERTANICAL emphasizes a global leadership position through a focused cannabinoid approach and a mission to significantly reduce the burden of chronic pain. The overarching goal is a world free of chronic pain.

Company size
11-50
Company stage
Not listed
Total funding
Not listed
Headquarters
Gräfelfing, Germany
Founded
2017

Recently Posted Jobs

Explore more opportunities at VERTANICAL

See more jobs